CDT Equity Inc. (NASDAQ:CDT) Sees Significant Decline in Short Interest

CDT Equity Inc. (NASDAQ:CDT) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totaling 62,947 shares, a decline of 43.5% from the December 15th total of 111,333 shares. Based on an average trading volume of 60,024 shares, the short-interest ratio is presently 1.0 days. Currently, 4.2% of the shares of the company are sold short. Currently, 4.2% of the shares of the company are sold short. Based on an average trading volume of 60,024 shares, the short-interest ratio is presently 1.0 days.

CDT Equity Price Performance

NASDAQ:CDT traded up $0.04 during trading hours on Friday, reaching $1.39. The company had a trading volume of 25,632 shares, compared to its average volume of 47,843. CDT Equity has a 1-year low of $1.24 and a 1-year high of $921.60. The business’s 50 day moving average price is $1.75 and its 200-day moving average price is $7.33. The firm has a market cap of $2.27 million, a PE ratio of 0.00 and a beta of 1.80.

CDT Equity (NASDAQ:CDT) last posted its earnings results on Thursday, November 13th. The company reported ($13.16) earnings per share for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CDT Equity in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Institutional Investors Weigh In On CDT Equity

An institutional investor recently bought a new position in CDT Equity stock. Apollon Wealth Management LLC bought a new stake in shares of CDT Equity Inc. (NASDAQ:CDT) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 107,454 shares of the company’s stock, valued at approximately $73,000. Apollon Wealth Management LLC owned 28.28% of CDT Equity as of its most recent SEC filing. Institutional investors own 3.29% of the company’s stock.

About CDT Equity

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.